FDA Week - 06/16/2017

Generic, PBM industries applaud decision, but . . .

Uncertainty, Gamesmanship Expected Due To SCOTUS Biosimilar Ruling

June 15, 2017
NEW YORK -- The Supreme Court's decision to punt on whether the so-called biosimilar patent dance is mandatory in the highly-watched Amgen v. Sandoz case leaves the state of play filled with "uncertainty and gamesmanship," but companies are still likely to follow the patent dance process, an attorney who represents innovator biologic companies said Monday (July 12). The attorney argued the ruling handed down Monday means that innovators will be entering patent litigation blind, and said the decision could affect...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting as congressional Republicans take another run at repealing Obamacare.